Stay updated with breaking news from Eva Mulder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, today announced that Dr. Paul Peter Tak, Citryll Board member since
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase
-- All dosing regimens were well-tolerated across the Phase 1 clinical study -- -- High local exposure to AGMB-129 in the ileum -- -- No clinically relevant systemic exposure to AGMB-129, confirming
Azafaros B.V. today announced two key appointments, further strengthening its senior management team. Dr. Christian Freitag joins the company as Chief Medical Officer and Dr. Kyle Landskroner has been
Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins